Advertisement
UK markets closed

  • FTSE 100

    8,203.93
    -37.33 (-0.45%)
     

  • FTSE 250

    20,786.65
    +176.31 (+0.86%)
     

  • AIM

    774.39
    +4.97 (+0.65%)
     

  • GBP/EUR

    1.1823
    +0.0025 (+0.22%)
     

  • GBP/USD

    1.2805
    +0.0044 (+0.35%)
     

  • Bitcoin GBP

    44,257.80
    -1,163.72 (-2.56%)
     

  • CMC Crypto 200

    1,179.14
    -29.56 (-2.45%)
     

  • S&P 500

    5,563.95
    +26.93 (+0.49%)
     

  • DOW

    39,317.40
    +9.40 (+0.02%)
     

  • CRUDE OIL

    83.70
    -0.18 (-0.21%)
     

  • GOLD FUTURES

    2,395.70
    +26.30 (+1.11%)
     

  • NIKKEI 225

    40,912.37
    -1.28 (-0.00%)
     

  • HANG SENG

    17,799.61
    -228.67 (-1.27%)
     

  • DAX

    18,475.45
    +24.97 (+0.14%)
     

  • CAC 40

    7,675.62
    -20.16 (-0.26%)
     
Money:

What the new Labour government means for your money

Now that the dust has settled on the election we can take stock of what a Labour win will mean for your finances

Ayala Pharmaceuticals and Advaxis Agree To Combine, Expect Uplisting On NASDAQ

Vandana Singh
·1-min read

  • Ayala Pharmaceuticals Inc (NASDAQ: AYLA) and Advaxis Inc (OTC: ADXS) have announced a merger agreement.

  • The merger would result in a combined company focusing predominantly on developing and commercializing Ayala's lead program AL102 to treat desmoid tumors and Advaxis's candidate ADXS-504 in development for prostate cancer.

  • Ayala's lead candidate, AL102, is currently being investigated in the Phase 2/3 RINGSIDE study in desmoid tumors.

  • The combined company has the cash to advance the combined portfolio through key milestones in 2023.

  • Each Ayala share will be converted into the right to receive Advaxis shares. Combined Company to Seek Uplisting to Nasdaq.

  • Upon completion of the merger, Ayala stockholders will own approximately 62.5% of the combined company, and Advaxis stockholders will own approximately 37.5%.

  • The board of directors of the combined company is expected to consist of seven members: two designated by Advaxis, four by Ayala, and Kenneth Berlin, President & CEO of Advaxis.

  • The management will include - Kenneth Berlin, President, CEO & Director; Andres Gutierrez, current Chief Medical Officer of Advaxis; Igor Gitelman, Interim Chief Financial Officer of Advaxis.

  • Roni Mamluk, Founder & CEO of Ayala, and Yossi Maimon, CFO of Ayala, will resign.

  • Gary Gordon, Chief Medical Officer of Ayala, will also resign but is expected to continue in an advisory role for some time.

  • Price Action: AYLA shares are down 28.70% at $0.65 on the last check Wednesday.

See more from Benzinga

ADVERTISEMENT

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.